Pharmacokinetic/pharmacodynamic predictors of time to clinical resolution in patients with acute bacterial exacerbations of chronic bronchitis treated with a fluoroquinolone

International Journal of Antimicrobial Agents

Volumn 16, Issue 3, 2000, Pages 273-280

  Meinl, Barbara ^a   Hyatt, Judith M ^a   Forrest, Alan ^a   Chodosh, Sanford ^b   Schentag, Jerome J ^a  

^a MILLARD FILLMORE HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic bronchitis; Pharmacodynamics fluoroquinolones; Pharmacokinetics fluoroquinolones

Indexed keywords

AMOXICILLIN; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; GREPAFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; CHRONIC BRONCHITIS; CLINICAL ARTICLE; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; LUNG ALVEOLUS MACROPHAGE; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RESPIRATORY FUNCTION; SPUTUM ANALYSIS;

ANTI-INFECTIVE AGENTS; BRONCHITIS; CHRONIC DISEASE; CONTROLLED CLINICAL TRIALS; FEMALE; FLUOROQUINOLONES; HAEMOPHILUS INFLUENZAE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MORAXELLA (BRANHAMELLA) CATARRHALIS; PIPERAZINES; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 0033746327     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00253-3     Document Type: Article

References (17)

1. Treatment of acute exacerbations of chronic bronchitis
2. Grepafloxacin - Focus on respiratory infections
3. Severe exacerbations of COPD patients: The role of pulmonary infections
4. Efficacy of ciprofloxacin and clarithromycin in acute bacterial exacerbations of complicated chronic bronchitis: Interim analysis
5. Surveillance of antimicrobial resistance in Streptococcus pneumonia, Haemophilus influenzae, and M. catarrhalis in the United States in 1997-1997 respiratory season
6. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males
7. Pharmacokinetics of grepafloxacin
8. Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin
9. Comparative in vitro activities of the new quinolone OPC-17116, possessing potent activity against Gram-positive bacteria
10. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis
11. Chronic bronchitis: Choosing the optimal treatment
12. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for the treatment of acute bacterial exacerbations of chronic bronchitis: Comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily
13. Chronic bronchitis: Key points in evaluation
14. Bronchiectasis
15. The damaging role of bacteria in chronic lung infection
16. Clinical, pathological, and microbiologic characterization of bronchiectasis in an aging cohort